Capillary electrophoresis on-line hyphenated with mass spectrometry for analysis of insulin-like growth factor-1 in pharmaceutical preparations.
antidoping
biopharmaceuticals
colostrum
mecasermin
pharmaceutical application
Journal
Electrophoresis
ISSN: 1522-2683
Titre abrégé: Electrophoresis
Pays: Germany
ID NLM: 8204476
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
15
06
2023
received:
29
04
2023
accepted:
22
06
2023
medline:
13
11
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
Insulin-like growth factor-1 (IGF-1) is a 70-amino acid single-chain polypeptide, which has found application in diagnostics as a biomarker of growth hormone disorders and as a therapy for growth failure in children and adolescents. Due to its strong anabolic effects, it is often abused by athletes for doping purposes. Here, we developed an on-line hyphenated method based on capillary zone electrophoresis (CZE) and triple quadrupole mass spectrometry (MS) detection with electrospray ionization (CZE-electrospray ionization source-MS [CZE-ESI-MS]) for the determination of IGF-1 in pharmaceutical matrices. We achieved a highly efficient, accurate, repeatable, sensitive, and selective analysis of IGF-1 with favorable migration times (<15 min). Optimized and validated CZE-ESI-MS method was successfully applied for the determination of IGF-1 in injectable solutions (Increlex®), and its presence was also confirmed in nutritional preparations (tablets and liquid colostrum). This is the first validated CZE-ESI-MS method for the determination of IGF-1 in pharmaceutical matrices revealing the potential of capillary electrophoresis for its use in drug quality control laboratories with benefits, such as high separation efficiency, high-speed analysis, low sample consumption, as well as environmental and cost aspects.
Identifiants
pubmed: 37433984
doi: 10.1002/elps.202300089
doi:
Substances chimiques
Insulin-Like Growth Factor I
67763-96-6
Peptides
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1674-1681Informations de copyright
© 2023 Wiley-VCH GmbH.
Références
Bailes J, Soloviev M. Insulin-like growth factor-1 (IGF-1) and its monitoring in medical diagnostic and in sports. Biomolecules. 2021;11:1-15.
Cowan DA, Moncrieffe DA. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration. Drug Test Anal. 2022;14:808-19.
Johannsson G, Bidlingmaier M, Biller BMK, Boguszewski M, Casanueva FF, Chanson P, et al. Growth hormone research society perspective on biomarkers of GH action in children and adults. Endocr Connect. 2018;7:R126-34.
Zumkeller W. IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? J Clin Pathol Mol Pathol. 2001;54:285-8.
Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346-53.
Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist. 2008;13:16-24.
Trejo JL, Carro E, Garcia-Galloway E, Torres-Aleman I. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J Mol Med. 2004;82:156-62.
Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939-44.
Vaessen N, Heutink P, Janssen JA, Witteman JCM, Testers L, Hofman A, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50:637-42.
Keating GM. Mecasermin. BioDrugs. 2008;22:177-88.
World Anti-Doping Agency. The prohibited list. World Anti-Doping Agency; 2022. https://www.wada-ama.org/en/what-we-do/prohibited-list (accessed 29 Aug2022)
Kašička V. Recent developments in capillary and microchip electroseparations of peptides (2019-mid 2021). Electrophoresis. 2022;43:82-108.
Štěpánová S, Kašička V. Applications of capillary electromigration methods for separation and analysis of proteins (2017-mid 2021) - a review. Anal Chim Acta. 2022;1209:339447.
Stutz H. Advances and applications of capillary electromigration methods in the analysis of therapeutic and diagnostic recombinant proteins-a review. J Pharm Biomed Anal. 2023;222:115089.
Thomas SL, Thacker JB, Schug KA, Maráková K. Sample preparation and fractionation techniques for intact proteins for mass spectrometric analysis. J Sep Sci. 2021;44:211-46.
Seyfinejad B, Jouyban A. Capillary electrophoresis-mass spectrometry in pharmaceutical and biomedical analyses. J Pharm Biomed Anal. 2022;221:115059.
Kuzyk VO, Somsen GW, Haselberg R. CE-MS for proteomics and intact protein analysis. Adv Exp Med Biol. 2021;1336:51-86.
Šlampová A, Malá Z, Gebauer P. Recent progress of sample stacking in capillary electrophoresis (2016-2018). Electrophoresis. 2019;40:40-54.
Miková B, Dvořák M, Ryšavá L, Malá Z, Gebauer P, Kubáň P. At-line coupling of hollow fiber liquid-phase microextraction to capillary electrophoresis for trace determination of acidic drugs in complex samples. Talanta. 2022;238:123068.
Shen X, Yang Z, McCool EN, Lubeckyj RA, Chen D, Sun L. Capillary zone electrophoresis-mass spectrometry for top-down proteomics. TrAC Trends Anal Chem. 2019;120:115644.
Chen D, McCool EN, Yang Z, Shen X, Lubeckyj RA, Xu T, et al. Recent advances (2019-2021) of capillary electrophoresis-mass spectrometry for multilevel proteomics. Mass Spectrom Rev. 2021;42:1-26.
Camperi J, De Cock B, Pichon V, Combes A, Guibourdenche J, Fournier T, et al. First characterizations by capillary electrophoresis of human chorionic gonadotropin at the intact level. Talanta. 2019;193:77-86.
Neusüß C, Demelbauer U, Pelzing M. Glycoform characterization of intact erythropoietin by capillary electrophoresis-electrospray-time of flight-mass spectrometry. Electrophoresis. 2005;26:1442-50.
Bracke N, Wynendaele E, D'Hondt M, Haselberg R, Somsen GW, Pauwels E, et al. Analytical characterization of NOTA-modified somatropins. J Pharm Biomed Anal. 2014;96:1-9.
Bush DR, Zang L, Belov AM, Ivanov AR, Karger BL. High resolution CZE-MS quantitative characterization of intact biopharmaceutical proteins: proteoforms of interferon-β1. Anal Chem. 2016;88:1138-46.
Fussl F, Trappe A, Carillo S, Jakes C, Bones J. Comparative elucidation of cetuximab heterogeneity on the intact protein level by cation exchange chromatography and capillary electrophoresis coupled to mass spectrometry. Anal Chem. 2020;92:5431-8.
Nashabeh W, Greve KF, Kirby D, Foret F, Karger BL, Reifsnyder DH, et al. Incorporation of hydrophobic selectivity in capillary electrophoresis: analysis of recombinant insulin-like growth factor I variants. Anal Chem. 1994;66:2148-54.
Roche ME, Anderson MA, Oda RP, Riggs LB, Strausbauch MA, Okazaki R, et al. Capillary electrophoresis of insulin-like growth factors: enhanced ultraviolet detection using dynamically coated capillaries and on-line solid-phase extraction. Anal Biochem. 1998;258:87-95.
Maráková K, Renner BJ, Thomas SL, Opetová M, Tomašovský R, Rai AJ, et al. Solid phase extraction as sample pretreatment method for top-down quantitative analysis of low molecular weight proteins from biological samples using liquid chromatography - triple quadrupole mass spectrometry. Anal Chim Acta. 2023;1243:340801.